BG103106A - Таблетки тровафлоксацин мезилат - Google Patents

Таблетки тровафлоксацин мезилат

Info

Publication number
BG103106A
BG103106A BG103106A BG10310699A BG103106A BG 103106 A BG103106 A BG 103106A BG 103106 A BG103106 A BG 103106A BG 10310699 A BG10310699 A BG 10310699A BG 103106 A BG103106 A BG 103106A
Authority
BG
Bulgaria
Prior art keywords
tablets
trovafloxacin mesilate
mesilate
trovafloxacin
compositions
Prior art date
Application number
BG103106A
Other languages
English (en)
Inventor
Alton JOHNSON
Christopher SINKO
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG103106A publication Critical patent/BG103106A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретението се отнася до състави, по-специално под формата на таблети, съдържащи полиморф II формата на тровафлоксацин мезилат, смазващо вещество имикрокристална целулоза (МС) като разтворител. Съставите, включващи МС като разтворител, имат добрастабилност при съхраняване на склад и при разтваряне. </P>
BG103106A 1998-01-21 1999-01-21 Таблетки тровафлоксацин мезилат BG103106A (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7201398P 1998-01-21 1998-01-21

Publications (1)

Publication Number Publication Date
BG103106A true BG103106A (bg) 1999-08-31

Family

ID=22105016

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103106A BG103106A (bg) 1998-01-21 1999-01-21 Таблетки тровафлоксацин мезилат

Country Status (34)

Country Link
US (1) US6187341B1 (bg)
EP (1) EP0930068A3 (bg)
JP (1) JPH11269072A (bg)
KR (1) KR100314977B1 (bg)
CN (1) CN1227743A (bg)
AP (1) AP1094A (bg)
AR (1) AR012780A1 (bg)
AU (1) AU758381B2 (bg)
BG (1) BG103106A (bg)
BR (1) BR9900116A (bg)
CA (1) CA2259698C (bg)
CO (1) CO4810225A1 (bg)
DZ (1) DZ2712A1 (bg)
EA (1) EA003247B1 (bg)
GT (1) GT199900004A (bg)
HR (1) HRP990023A2 (bg)
HU (1) HUP9900154A3 (bg)
ID (1) ID23735A (bg)
IL (1) IL128051A0 (bg)
IS (1) IS4947A (bg)
MA (1) MA24747A1 (bg)
NO (1) NO990243L (bg)
NZ (1) NZ333838A (bg)
OA (1) OA10958A (bg)
PA (1) PA8466701A1 (bg)
PE (1) PE20000169A1 (bg)
PL (1) PL330981A1 (bg)
SG (1) SG70666A1 (bg)
SK (1) SK4299A3 (bg)
TN (1) TNSN99007A1 (bg)
TR (1) TR199900089A2 (bg)
TW (1) TW518224B (bg)
YU (1) YU2399A (bg)
ZA (1) ZA99393B (bg)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200101310T2 (tr) * 1998-11-10 2001-10-22 Bayer Aktiengesellschaft Farmasötik moksifloksasin preparatı.
EP1216058A2 (en) * 1999-09-20 2002-06-26 Alza Corporation Process for lessening polymorphic conversion of a drug
ATE285821T1 (de) * 1999-10-08 2005-01-15 Affinium Pharm Inc Fab i inhibitoren
FR2808441B1 (fr) * 2000-05-04 2004-06-18 Oreal Utilisation de fibres dans une composition de soin ou de maquillage pour matifier la peau
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
CA2444597A1 (en) * 2001-04-06 2002-10-06 Affinium Pharmaceuticals, Inc. Fab i inhibitors
EP1396263A1 (en) 2002-08-09 2004-03-10 Warner-Lambert Company Film coating for tablets and caplets
EP1575951B1 (en) 2002-12-06 2014-06-25 Debiopharm International SA Heterocyclic compounds, methods of making them and their use in therapy
CN100415284C (zh) * 2002-12-30 2008-09-03 毛友昌 六味木香片的制备方法
DE602004016831D1 (de) 2003-03-17 2008-11-13 Affinium Pharm Inc Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
ES2297067T3 (es) * 2003-03-19 2008-05-01 The Jordanian Pharmaceutical Manufacturing Co. Ltd. Composiciones farmaceuticas no higroscopicas que contienen acidos quinolinacarboxilicos de hidratados.
US8906413B2 (en) * 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
WO2005009395A2 (en) * 2003-07-23 2005-02-03 L. Perrigo Company Cellulosic fiber containing composition
EP2848614A3 (en) 2004-06-04 2015-07-29 Debiopharm International SA Acrylamide derivatives as antibiotic agents
WO2006044805A2 (en) * 2004-10-15 2006-04-27 Supernus Pharmaceuticals, Inc. Less abusable pharmaceutical preparations
EP1973902A2 (en) * 2005-12-05 2008-10-01 Affinium Pharmaceuticals, Inc. 3-heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
WO2008098374A1 (en) 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
SI2861608T1 (sl) 2012-06-19 2019-08-30 Debiopharm International Sa Derivati predzdravila (E)-N-metil-N-((3-metilbenzofuran-2-IL)metil)- 3-(7-okso-5,6,7,8-tetrahidro-1 ,8-nafthiridin-3-il)akrilamid
BR122023021456A2 (pt) 2016-02-26 2024-02-20 Debiopharm International S.A. Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica
LT3923914T (lt) 2019-02-14 2023-07-25 Debiopharm International S.A. Afabicino kompozicija, jos gamybos būdas
CN113939306B (zh) 2019-06-14 2024-07-19 德彪药业国际股份公司 用于治疗涉及生物膜的细菌感染的药物及其用途
JP2025529185A (ja) * 2022-08-30 2025-09-04 パンネックス セラピューティクス インコーポレイテッド パネキシン－１調節剤及びパネキシン－１が関与する疾患の治療方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601566A1 (de) * 1986-01-21 1987-07-23 Bayer Ag Pharmazeutische zubereitungen von ciprofloxacin
US5286754A (en) 1986-01-21 1994-02-15 Bayer Aktiengesellschaft Pharmaceutical formulations of ciprofloxacin
US4957554A (en) 1989-08-16 1990-09-18 Minnesota Mining And Manufacturing Company Dimensionally-controlled ceramics
DE4120646A1 (de) 1991-06-22 1992-12-24 Bayer Ag 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
SK23898A3 (en) * 1995-08-29 1999-05-07 Pfizer Zwitterionic forms of trovafloxacin

Also Published As

Publication number Publication date
PA8466701A1 (es) 2000-09-29
DZ2712A1 (fr) 2003-09-01
AP9901443A0 (en) 1999-03-31
CN1227743A (zh) 1999-09-08
EA003247B1 (ru) 2003-02-27
AP1094A (en) 2002-08-19
IS4947A (is) 1999-07-22
HRP990023A2 (en) 1999-08-31
HUP9900154A2 (hu) 1999-09-28
EA199900046A3 (ru) 1999-12-29
CA2259698A1 (en) 1999-07-21
JPH11269072A (ja) 1999-10-05
NZ333838A (en) 2000-03-27
TR199900089A3 (tr) 1999-10-21
IL128051A0 (en) 1999-11-30
BR9900116A (pt) 2000-05-02
KR100314977B1 (ko) 2001-11-24
NO990243L (no) 1999-07-22
HU9900154D0 (en) 1999-03-29
TW518224B (en) 2003-01-21
PE20000169A1 (es) 2000-03-10
AU1217399A (en) 1999-08-12
NO990243D0 (no) 1999-01-20
TNSN99007A1 (fr) 2005-11-10
ID23735A (id) 2000-05-11
OA10958A (en) 2001-10-31
EA199900046A2 (ru) 1999-08-26
TR199900089A2 (xx) 1999-10-21
AR012780A1 (es) 2000-11-08
GT199900004A (es) 2000-07-08
US6187341B1 (en) 2001-02-13
YU2399A (sh) 2002-06-19
EP0930068A3 (en) 1999-12-22
MA24747A1 (fr) 1999-10-01
EP0930068A2 (en) 1999-07-21
SG70666A1 (en) 2000-02-22
SK4299A3 (en) 2000-06-12
AU758381B2 (en) 2003-03-20
KR19990068014A (ko) 1999-08-25
CO4810225A1 (es) 1999-06-30
PL330981A1 (en) 1999-08-02
ZA99393B (en) 2000-07-21
CA2259698C (en) 2003-04-15
HUP9900154A3 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
BG103106A (bg) Таблетки тровафлоксацин мезилат
TR200103186T2 (tr) MEK enzimlerinin inhibitörleri olarak kinolin türevleri
BG103413A (bg) Производни на сулфиновата киселина, тяхното получаване и използване
HK1039110A1 (zh) 以新颖的合成物及组分作为蛋白酶抑制剂
AU2002220715A1 (en) Indolsulfonyl compounds useful in the treatment of cns disorders
GEP20033000B (en) 2-Substituted-1-Piperidyl Benzimidazole Compounds as ORL1-Receptor Agonists
DE3474631D1 (en) N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
BG106013A (bg) Нови съединения и състави като протеазни инхибитори
AU6011301A (en) 1,2,3,4-tetrahydroisoquinoline derivatives
IS7545A (is) 7-Arýl-3,9-díasabísýkló(3.3.1)nón-6-en afleiður og notkun þeirra sem renín hindra í meðferð á háþrýstingi, hjarta- og æða- eða nýrna sjúkdómum
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
AU2003269327A1 (en) Tetrahydroquinoline derivatives as crth2 antagonists
MY133996A (en) Compounds for the treatment of ischemia
IL114599A0 (en) Substituted pyrimidine compounds their preparation and pharmaceutical compositions containing them
HUP0103913A3 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
FI970147A0 (fi) Triatsoliyhdisteitä ja niiden käyttö dopamiini-D3-ligandeina
CA2390649A1 (en) 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
CA2378428A1 (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
BG106239A (bg) Подобрени фармацевтични състави
AU5915100A (en) Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
CA2378834A1 (en) Pyrazinones, compositions containing such compounds
PT1427417E (pt) Derivados de 6, 7-di-hidroxitetra-hidroisoquinolina substituída em 3 para utilização como agentes antibacterianos
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
MXPA02004441A (es) Derivados de isoxazol como inhibidores de la fosfodiesterasa.